Opinion|Videos|August 14, 2024
EMA vs Telomerase Inhibitor for RS+ patients after ESA failure
Author(s)Abdulraheem Yacoub, MD
Advertisement
Episodes in this series
- With the advent of new options for treatment after ESAs for patients with LR-MDS, please share your thoughts about the choice between an EMA versus a telomerase inhibitor in the RS positive patient?
Advertisement
Related to this article
Erik S. Mittra, MD, PhD, highlighted how new PRRT trials may reshape neuroendocrine tumor care, from retreatment and dosimetry to alpha-emitting therapies.
Advertisement
Advertisement
Trending on Targeted Onc
1
NETs Year in Review: RLT Advances as Combo Strategies and ICIs Show Limited Benefit
2
Dr Dasari on Emerging PRRT Options and New Therapeutic Targets in NETs
3
Dr Chauhan on Oncolytic Virus SVV-001 Plus Ipi/Nivo in Neuroendocrine Cancers
4
Real-World Data Reveal Risk Factors for Myeloid Neoplasm After Lutetium Lu 177 Dotatate
5